Tumors with a paucity of infiltrating T‐cells, such as RAS‐driven tumors, have high surface levels of immune checkpoint molecules such as PD‐L1 and B7‐H3 and respond poorly to current cancer treatments such as chemotherapy and immunotherapy.35, 66. The gene discussed is CD276; the disease is cancer.